Differences in Detection Patterns, Characteristics, and Outcomes of Central and Peripheral Lung Cancers in Low-dose Computed Tomography Screening

Overview

Journal Transl Lung Cancer Res

Date 2022 Jan 10

PMID 35004249

Authors

Yeon Wook Kim

Minhee Jeon

Myung Jin Song

Byoung Soo Kwon

Sung Yoon Lim

Yeon Joo Lee

Jong Sun Park

Young-Jae Cho

Ho Il Yoon

Kyung Won Lee

Jae Ho Lee

Choon-Taek Lee

Affiliations

Soon will be listed here.

Abstract

Background: Although low-dose computed tomography (LDCT) screening is known to be effective for the detection of lung cancers localized in peripheral lung regions at a curable stage, limited data is available regarding the characteristics and outcomes of central lung cancers diagnosed in a screening cohort. This study aimed to determine whether LDCT screening could effectively detect central lung cancers at an early stage and offer survival benefits.

Methods: We analyzed 52,615 adults who underwent lung cancer screening with LDCT between May 2003 and Dec 2019 at a tertiary center in South Korea. Characteristics and outcomes of those diagnosed with lung cancer, stratified by screen-detection status and cancer location, were evaluated.

Results: A total of 352 individuals (281 screen-detected, 71 non-screen-detected) were diagnosed with lung cancer. Compared to screen-detected cancers, non-screen-detected cancers tended to be centrally-located (11.4% vs. 64.8%, P<0.001). Most non-screen-detected central cancers (89.1%) had a negative result on prior LDCT screening. Multivariable regression analyses revealed that for peripheral cancers, screen-detection was associated with a significantly lower probability of diagnosis at an advanced stage [III/IV, odds ratio (OR) =0.15, 95% confidence interval (CI): 0.05-0.45] and mortality [hazard ratio (HR) =0.33, 95% CI: 0.13-0.84]; however, the association was insignificant for central cancers. For screen-detected cancers, central location, compared to peripheral location, was significantly associated with a higher risk of diagnosis at an advanced stage (OR =20.83, 95% CI: 6.67-64.98) and mortality (HR =4.98, 95% CI: 2.26-10.97).

Conclusions: Unlike for peripheral cancers, LDCT screening did not demonstrate an improvement in outcomes of central lung cancers, indicating an important limitation of LDCT screening and the need for developing novel modalities to screen and treat central lung cancer.

Citing Articles

Endobronchial ultrasound: a pictorial essay.

Fantin A, Castaldo N, Tirone C, Sartori G, Crisafulli E, Patrucco F Acta Biomed. 2023; 94(4):e2023113.

PMID: 37539612 PMC: 10440771. DOI: 10.23750/abm.v94i4.14090.

Kurihara Y, Tashiro H, Takahashi K, Tajiri R, Kuwahara Y, Kajiwara K Thorac Cancer. 2022; 13(24):3459-3466.

PMID: 36263938 PMC: 9750813. DOI: 10.1111/1759-7714.14705.

The value of narrow-band imaging bronchoscopy in diagnosing central lung cancer.

Zhu J, Liu R, Wu X, Li Q, Gong B, Shen Y Front Oncol. 2022; 12:998770.

PMID: 36185220 PMC: 9524255. DOI: 10.3389/fonc.2022.998770.

References

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

Cuffe S, Moua T, Summerfield R, Roberts H, Jett J, Shepherd F . Characteristics and outcomes of small cell lung cancer patients diagnosed during two lung cancer computed tomographic screening programs in heavy smokers. J Thorac Oncol. 2011; 6(4):818-22. DOI: 10.1097/JTO.0b013e31820c2f2e. View

Sun W, Yang X, Liu Y, Yuan Y, Lin D . Primary Tumor Location Is a Useful Predictor for Lymph Node Metastasis and Prognosis in Lung Adenocarcinoma. Clin Lung Cancer. 2016; 18(1):e49-e55. DOI: 10.1016/j.cllc.2016.06.002. View

Schabath M, Massion P, Thompson Z, Eschrich S, Balagurunathan Y, Goldof D . Differences in Patient Outcomes of Prevalence, Interval, and Screen-Detected Lung Cancers in the CT Arm of the National Lung Screening Trial. PLoS One. 2016; 11(8):e0159880. PMC: 4980050. DOI: 10.1371/journal.pone.0159880. View

Kang H, Cho J, Lee S, Lee Y, Park J, Cho Y . Role of Low-Dose Computerized Tomography in Lung Cancer Screening among Never-Smokers. J Thorac Oncol. 2018; 14(3):436-444. DOI: 10.1016/j.jtho.2018.11.002. View

Shin S, Jeong D, Lee K, Cho J, Choi Y, Lee K . Which definition of a central tumour is more predictive of occult mediastinal metastasis in nonsmall cell lung cancer patients with radiological N0 disease?. Eur Respir J. 2019; 53(3). PMC: 6422838. DOI: 10.1183/13993003.01508-2018. View

Henschke C, Yankelevitz D, Yip R, Reeves A, Farooqi A, Xu D . Lung cancers diagnosed at annual CT screening: volume doubling times. Radiology. 2012; 263(2):578-83. PMC: 3329268. DOI: 10.1148/radiol.12102489. View

Silva M, Galeone C, Sverzellati N, Marchiano A, Calareso G, Sestini S . Screening with Low-Dose Computed Tomography Does Not Improve Survival of Small Cell Lung Cancer. J Thorac Oncol. 2016; 11(2):187-93. DOI: 10.1016/j.jtho.2015.10.014. View

Henschke C, Yankelevitz D, Libby D, Pasmantier M, Smith J, Miettinen O . Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006; 355(17):1763-71. DOI: 10.1056/NEJMoa060476. View

10.

Socinski M, Obasaju C, Gandara D, Hirsch F, Bonomi P, Bunn Jr P . Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. J Thorac Oncol. 2017; 13(2):165-183. DOI: 10.1016/j.jtho.2017.11.111. View

11.

Patz Jr E, Pinsky P, Gatsonis C, Sicks J, Kramer B, Tammemagi M . Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med. 2013; 174(2):269-74. PMC: 4040004. DOI: 10.1001/jamainternmed.2013.12738. View

12.

Wu F, Kuo P, Huang Y, Tang E, Chen C, Wu M . Differences in lung cancer characteristics and mortality rate between screened and non-screened cohorts. Sci Rep. 2019; 9(1):19386. PMC: 6920422. DOI: 10.1038/s41598-019-56025-6. View

13.

Wu F, Huang Y, Wu C, Tang E, Chen C, Mar G . Assessment of Selection Criteria for Low-Dose Lung Screening CT Among Asian Ethnic Groups in Taiwan: From Mass Screening to Specific Risk-Based Screening for Non-Smoker Lung Cancer. Clin Lung Cancer. 2016; 17(5):e45-e56. DOI: 10.1016/j.cllc.2016.03.004. View

14.

Martinez-Zayas G, Almeida F, Simoff M, Yarmus L, Molina S, Young B . A Prediction Model to Help with Oncologic Mediastinal Evaluation for Radiation: HOMER. Am J Respir Crit Care Med. 2019; 201(2):212-223. PMC: 6961739. DOI: 10.1164/rccm.201904-0831OC. View

15.

Sun S, Schiller J, Gazdar A . Lung cancer in never smokers--a different disease. Nat Rev Cancer. 2007; 7(10):778-90. DOI: 10.1038/nrc2190. View

16.

Casal R, Vial M, Miller R, Mudambi L, Grosu H, Eapen G . What Exactly Is a Centrally Located Lung Tumor? Results of an Online Survey. Ann Am Thorac Soc. 2016; 14(1):118-123. DOI: 10.1513/AnnalsATS.201607-568BC. View

17.

Nicholson A, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A . The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung.... J Thorac Oncol. 2016; 11(3):300-11. DOI: 10.1016/j.jtho.2015.10.008. View

18.

Wu F, Huang Y, Wu Y, Tang E, Wu M, Chen C . Prognostic effect of implementation of the mass low-dose computed tomography lung cancer screening program: a hospital-based cohort study. Eur J Cancer Prev. 2020; 29(5):445-451. DOI: 10.1097/CEJ.0000000000000569. View

19.

Casal R, Sepesi B, Sagar A, Tschirren J, Chen M, Li L . Centrally located lung cancer and risk of occult nodal disease: an objective evaluation of multiple definitions of tumour centrality with dedicated imaging software. Eur Respir J. 2019; 53(5). DOI: 10.1183/13993003.02220-2018. View

20.

Marquette C, Boutros J, Benzaquen J, Ferreira M, Pastre J, Pison C . Circulating tumour cells as a potential biomarker for lung cancer screening: a prospective cohort study. Lancet Respir Med. 2020; 8(7):709-716. DOI: 10.1016/S2213-2600(20)30081-3. View